STRATEC SE

M&A Activity • Mar 13, 2006

News Details

Ad-hoc | 13 March 2006 11:38

STRATEC takes over Sanguin International

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC takes over Sanguin International Birkenfeld, March 13, 2006 STRATEC Biomedical Systems AG has today taken over Sanguin International Limited (http://www.sanguin.com), Barton under Needwood, UK, including its 75% shareholding in Sanguin International Incorporation, Hamden, CT, USA. The acquisition price, which is partly dependent on the earnings generated by Sanguin for the 2005/2006 financial year and on the progress made with a software integration project at the company thereby taken over, will largely be settled in cash. STRATEC will pay the other part of the acquisition price with a total of 18,206 new shares to be created from the authorized capital of STRATEC Biomedical Systems AG. These shares will be subject to a lock-up period. The parties have agreed to maintain confidentiality as to the acquisition price. ————————————————————————— Informationen und Erläuterungen des Emittenten zu dieser Ad-Hoc-Mitteilung: STRATEC expects the takeover to generate savings of more than EUR 3 million in the implementation of analyzer system families in the development and planning stages. In particular, the combination of Sanguin software with STRATEC technology will enable both companies to participate with a complementary product portfolio for the clinical diagnostic laboratory. Sanguin is currently one of the few companies to offer FDA-approved software solutions capable of deployment in networks by diagnostics companies around the world, especially in the field of blood bank applications. In the blood bank field, for example, Sanguin is the global market leader, with more than 3,000 software packages. ‘One of our customers, who is at the same time also a customer of Sanguin, mentioned to me some time ago that Sanguin already defines the standards today, and will continue to define them in future. The extensive functionality of the software solutions offered by Sanguin cannot be matched by any other company in the market’, commented Hermann Leistner, Chairman of the Board of Management of STRATEC Biomedical Systems AG. Sanguin maintains active business relationships with several of the world’s largest diagnostics companies. With customer structures which complement each other ideally, the STRATEC Group now has business relationships with seven of the world’s ten largest diagnostics companies in terms of sales. The wholly-owned subsidiary STRATEC Biomedical Inc., Aliquippa, PA, USA, which was established by STRATEC in 1996, will relocate its business operations in the coming months to Hamden, CT, USA, where Sanguin International Inc. is also based. This measure will spare STRATEC the time-consuming and costly process of expanding its representation in the USA. The previous managing directors of the two Sanguin companies will be fully available to the STRATEC on an operational level and will assist in pressing ahead with the further strategic expansion of the Group. The parties to the agreement expect Sanguin to generate consolidated operating earnings of more than GBP 500,000 in the 2005/2006 financial year. Telephone conference – Marcus Wolfinger, CFO of STRATEC Biomedical Systems AG, will be available to provide further information in connection with this ad-hoc announcement in a telephone conference to be held today, Monday, March 13, 2006 at 3 p.m. (conference language: German). The dial-in number is: +49 (0) 69 58 999 0808. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the wholly-owned subsidiaries ‘STRATEC NewGen GmbH’ and ‘Robion AG’. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 (0)7082 7916 190 Fax: +49 (0)7082 7916 999 E-mail: ir@stratec-biomedical.de (c)DGAP 13.03.2006 ————————————————————————— language: English emitter: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland phone: +49 (0)7082 7916 0 fax: +49 (0)7082 7916 999 email: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 indexes: stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————